Amarin Appoints New CMO, Director; Discloses Officer Compensation

TL;DR

Amarin beefs up leadership with a new CMO and board member, check compensation details.

AI Summary

Amarin Corporation plc announced on June 3, 2024, the appointment of Dr. Steven L. Smith as Chief Medical Officer and the election of Ms. Anya V. Schiess as a new director to its Board of Directors. The company also disclosed details regarding compensatory arrangements for certain officers.

Why It Matters

The appointment of a new Chief Medical Officer and a board director signals potential strategic shifts or leadership changes within Amarin, which could impact the company's future drug development and business strategy.

Risk Assessment

Risk Level: medium — Changes in key leadership roles and disclosure of compensatory arrangements can indicate internal shifts that may affect future performance or strategy.

Key Players & Entities

• Amarin Corporation plc (company) — Registrant
• Dr. Steven L. Smith (person) — Appointed Chief Medical Officer
• Ms. Anya V. Schiess (person) — Elected to Board of Directors
• June 3, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $1 billion — in driving annual revenues approaching $1 billion until the acquisition of Kos Pharmaceut

Filing Documents

• amrn-20240603.htm (8-K) — 53KB
• amrn-ex99_1.htm (EX-99.1) — 17KB
• img114078973_0.jpg (GRAPHIC) — 27KB
• 0000950170-24-068298.txt ( ) — 238KB
• amrn-20240603.xsd (EX-101.SCH) — 32KB
• amrn-20240603_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure The Company has been informed by a large national pharmacy benefit manager ("PBM") that, effective July 1, 2024, the PBM intends to no longer cover VASCEPA as the exclusive icosapent ethyl product for its Commercial national formularies and will be transitioning VASCEPA to not covered as of July 1, 2024. Currently, VASCEPA volume through these formularies represents approximately 25% of aggregate U.S. VASCEPA prescription volume. This decision does not impact VASCEPA coverage within Medicare Part D formularies of the PBM. The information set forth under this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No . Description 99.1 Press release, dated June 4, 2024 (furnished herewith). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * * * ACTIVE/122789132.1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 4, 2024 Amarin Corporation plc By: /s/ Aaron Berg Aaron Berg President and Chief Executive Officer ACTIVE/122789132.1

View Full Filing

View this 8-K filing on SEC EDGAR